Professor Fabienne Mackay obtained her PhD from Louis Pasteur University in Strasbourg, France. She is Head of the School of Biomedical Sciences in the Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Australia. Her laboratory dissected the functions of BAFF and its receptors in health and disease and these findings were described in very highly cited articles. A BAFF inhibitor was approved by the FDA on March 9th 2011: a first new treatment for lupus in over 50 years. Professor Mackay’s group is focusing on new inhibitors for the BAFF receptor TACI to treat Systemic Lupus Erythematosus (SLE) without compromising key immune function and, therefore, an approach that has a better safety profile. Her research and teaching directly influence clinical practice and she continues to make internationally significant contributions to the field of autoimmunity and oncology, with a strong record of knowledge translation and community engagement. She received the Thomson Reuters Australia citation and innovation award and a trophy from the French Ministry of Foreign Affairs in Paris for outstanding contribution in education and research as an expatriate. She was also recently elected as Council Member of the International Cytokine & Interferon Society.